List of medicinal products under additional monitoring

Human medicines European public assessment report (EPAR): Nuceiva, botulinum toxin type a, Skin Aging, Date of authorisation: 27/09/2019, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Trumenba, meningococcal group b vaccine (recombinant, adsorbed), Meningitis, Meningococcal, Date of authorisation: 24/05/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Microscopic Polyangiitis;Wegener Granulomatosis, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised

Etoposide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001333/202302

Etoposide : List of nationally authorised medicinal products - PSUSA/00001333/202302

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 13/07/2017, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell;Wegener Granulomatosis;Microscopic Polyangiitis;Pemphigus, Date of authorisation: 15/06/2017, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Trizivir, abacavir (as sulfate) / lamivudine / zidovudine, HIV Infections, Date of authorisation: 27/12/2000, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Trixeo Aerosphere, formoterol,glycopyrronium bromide,budesonide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 09/12/2020, Revision: 5, Status: Authorised